SAGE Therapeutics

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel medicines. It targets diseases and disorders of the brain with three key focus areas: depression, neurology, and neuropsychiatry. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010, and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

SAGE Therapeutics poised for Zuranolone launch in 2023, overcoming challenges

SAGE Therapeutics showcased strong financial performance and promising developments with Zuranolone, positioning the drug favorably for potential launch in 2023.
While facing challenges such as enrollment issues and DEA scheduling impacts, the company is leveraging opportunities in commercialization strategies and post-marketing studies to enhance Zuranolone's market presence.
Overall, Zuranolone's rapid and durable effects, alignment with current treatment practices, and targeted commercialization approach present a compelling opportunity for SAGE Therapeutics in the mental health treatment landscape.
By addressing challenges effectively and capitalizing on opportunities, SAGE Therapeutics is poised to make a significant impact in advancing treatments for mood disorders and improving patient outcomes.

Sage Therapeutics reports strong Q1 performance and eyes market expansion

Sage Therapeutics had a strong Q1 2023, focusing on brain health medicines and preparing for zuranolone's launch.
The company's financial position is solid, with growth opportunities in pipeline programs and proactive payer engagements.
Challenges include regulatory uncertainties and competition, but Sage is well-positioned to capitalize on market demand.
Opportunities lie in expanding product indications, proactive agreements with payers, and learning from competitors for strategic advantage.

SAGE Therapeutics to Launch Zurzuvae for Postpartum Depression, Overcomes FDA Setback

SAGE Therapeutics is poised to launch Zurzuvae for postpartum depression, leveraging its financial strength and clinical success. While facing challenges in MDD, the company is strategically adapting to focus on PPD and enhance operational efficiency. Opportunities lie in collaborations, pricing strategies, and addressing the significant market need for PPD treatments.

SAGE Therapeutics advances women's health with ZURZUVAE approval

SAGE Therapeutics navigates financial challenges while advancing innovative treatments for women's health.
ZURZUVAE's approval and commercialization plans present opportunities in a significant market segment.
Strategic focus on engagement, access, and market positioning key to ZURZUVAE's success.
Pipeline advancements and collaboration efforts position SAGE for future growth and impact.

SAGE Therapeutics excels with ZURZUVAE launch, poised for continued growth

SAGE Therapeutics had a strong performance in 2023, driven by the successful launch of ZURZUVAE and positive early market reception.
While facing challenges in data tracking and market competition, the company's focus on innovation and patient access presents growth opportunities.
With a robust pipeline and strategic initiatives in place, SAGE is well-positioned to maintain momentum and drive further success in the brain health space.

SAGE Therapeutics reports strong Zurzuvae launch amidst Parkinson's study setback

SAGE Therapeutics is navigating challenges from the PRECEDENT study while capitalizing on Zurzuvae's successful launch for PPD.
The company's pipeline progress and commitment to addressing cognitive disorders in neurodegenerative diseases showcase a strong focus on brain health.
Collaborative efforts with Biogen, strong payer coverage, and positive market feedback position Zurzuvae as a frontline treatment for PPD.
Strategic initiatives to educate prescribers, expand market reach, and refine study designs present promising growth opportunities for SAGE.

SAGE Therapeutics faces setbacks but sees success with ZURZUVAE in Q2

SAGE Therapeutics navigates setbacks with SAGE-324 study closure but sees success with ZURZUVAE in PPD treatment. Strong financial foundation and commitment to brain health initiatives position the company for future growth.

SAGE Therapeutics focuses on Zurzuvae for PPD treatment success

SAGE Therapeutics prioritizes Zurzuvae for PPD, showing strong revenue growth and prescription uptake
Challenges include discontinuation of certain programs and mixed results in clinical studies
Opportunities lie in focusing resources, upcoming study results, and strategic program ownership
Overall, SAGE's reorganization reflects a strategic shift towards maximizing Zurzuvae's potential

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. It focuses on diseases and disorders of the brain. Its products include ZURZUVAE and ZULRESSO. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.

Sage said Thursday it will cut about 40% of its workforce following a setback for depression treatment Zurzuvae. Sage stock edged higher.

Sage Therapeutics Cuts Workforce By 40% Following Rejection In Depression Treatment

SAGE Therapeutics (NASDAQ:SAGE) has announced a major reorganization, including laying off about 40% of its workforce, after the US Food & Drug Administration rejected its drug application for major depressive disorder (MDD). The reorganization, which has also resulted in a shake-up of its C-suite executives, is aimed at making the company leaner as it focuses the drug, to be marketed as Zurzuvae (zuranolone), on the less lucrative postpartum depression (PPD) market.

Sage Therapeutics to lay off 40% of staff after FDA rejects Zurzuvae  for 'major depressive disorder'

Sage Therapeutics Inc. SAGE, -0.70% said Thursday it is reorganizing its business operations and workforce as it gears up for the launch of its post partum depression treatment Zurzuvae in late 2023. The move includes a 40% reduction in its workforce as well as a plan to advance SAGE-718 and SAGE-324, while pausing other earlier-stage programs.

Sage Therapeutics to lay off 40% of staff as it gears up for launch of post-partum depression treatment

Sage Therapeutics said on Thursday it would cut its workforce by about 40%, weeks after the U.S. health regulator declined to approve its drug to treat major depressive disorder.

Sage Therapeutics to cut 40% of jobs after depression drug setback

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), today announced plans to reorganize its business operations and pipeline priorities to support goals for long-term business growth, including the planned commercial launch of ZURZUVAE for women with postpartum depression (PPD) in late 2023. “Our goal is to think big, start small and scale fast as we look to launch ZURZUVAE and help women suffering with PPD . Executing on launch and our potential long-term growth catalyst.

Sage Therapeutics Implements Strategic Reorganization to Support Plans for ZURZUVAE™ Commercial Launch and Pipeline Advancement

Apellis Pharma

Revance Therapeutics

In the financial markets, not everything always goes up, not everything always goes down. The fluctuations in the share prices of listed companies are constant.

3 Very Oversold Pharma Stocks to Buy Right Now

The Food and Drug Administration only granted partial approval to zuranolone this month. Sage is an unprofitable business, so it's a big blow that ensures the company's operations remain in the red for the foreseeable future.

Is Sage Therapeutics Stock in Trouble After Dropping 50% in a Month?

NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Sage Therapeutics, Inc. (“Sage” or the “Company”) (NASDAQ: SAGE) on behalf of Sage stockholders. Our investigation concerns whether Sage has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On August 4, 2023, Sage issued a press release disclosing that the U.S.

SAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating Sage Therapeutics, Inc. on Behalf of Sage Stockholders and Encourages Investors to Contact the Firm

SAN DIEGO , Aug. 18, 2023 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Sage Therapeutics, Inc. (NASDAQ: SAGE) focused on whether Sage Therapeutics and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in this investigation or if you are a Sage Therapeutics investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-sage-therapeutics-inc-investigation-sage.html You can also contact attorney J.C.

SAGE INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Announces Investigation into Sage Therapeutics, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

SAN DIEGO--(BUSINESS WIRE)--Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Sage Therapeutics, Inc. (NASDAQ: SAGE) focused on whether Sage Therapeutics and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in this investigation or if you are a Sage Therapeutics investor who suffered a loss and would like t.

SAGE INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Sage Therapeutics, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

Sage Therapeutics, Inc. has a virtual monopoly in treating postpartum depression, a condition that affects 15%-20% of postpartum women. The company's pipeline focuses on treating CNS disorders by modulating GABA and NMDA receptors. The major depression and essential tremor indications should further boost the stock price.

Sage Therapeutics: Undeserving Selloff Presents A Buying Opportunity

The FDA approved Zurzuvae for postpartum depression but not for major depressive disorder. Sage saw revenues and net losses climb in the second quarter.

Why Shares of Sage Therapeutics Slumped This Week

Novavax

Novavax's prospects in the coronavirus vaccine market look dim. Sage Therapeutics' recent regulatory news was a major blow to its prospects.

2 Beaten-Down Stocks That Still Aren't Worth Buying

Last Friday, Sage Therapeutics announced the FDA rejected its major depressive disorder drug candidate, zuranolone. In response, the drugmaker's shares cratered Monday.

Is Sage Therapeutics a Contrarian Buy?

Sage Therapeutic shares fell to an all-time low after the FDA rejected use of its treatment for major depressive disorder.

Sage Therapeutics Shares Plummet Following FDA Decision on Depression Drug

VistaGen Therapeutics

Sage Therapeutics Inc (NASDAQ:SAGE) is crumbling to record lows today, down 52.2% at $17.25 at last check, earlier hitting a low of $16.69.

2 Biotech Stocks Staging Large Swings

Sage Therapeutics, Inc. (NASDAQ:SAGE ) Business Update Call August 8, 2023 8:00 PM ET Company Participants Ashley Kaplowitz - Investor Relations Barry Greene - Chief Executive Officer Laura Gault - Chief Medical Officer Chris Benecchi - Chief Business Officer Kimi Iguchi - Chief Financial Officer Conference Call Participants Salveen Richter - Goldman Sachs Ritu Baral - TD Cowen Paul Matteis - Stifel Yasmeen Rahimi - Piper Sandler Anupam Rama - JPMorgan Tazeen Ahmad - Bank of America Brian Abrahams - RBC Capital Markets Jay Olson - Oppenheimer Sumant Kulkarni - Canaccord Laura Chico - Wedbush Securities Eason Lee - Needham & Company Marc Goodman - Leerink Akash Tewari - Jefferies Tim Lugo - William Blair George Farmer - Scotiabank Uy Ear - Mizuho Yatin Suneja - Guggenheim Operator Good morning, and welcome to Sage Therapeutics Business Update. Currently, all participants are in a listen-only mode.

Sage Therapeutics, Inc. (SAGE) Business Update Call (Transcript)

The U.S. FDA didn't approve zuranolone in treating major depressive disorder. However, the FDA did approve the drug in treating postpartum depression.

Why Sage Therapeutics Stock Is Crashing Today

The FDA approved the pill Zuranolone, developed by Sage and Biogen, for postpartum depression but declined to approve it for major depressive disorder.

Sage Therapeutics stock plunges 48% after FDA decision on postpartum depression drug

Sage Therapeutics (NASDAQ: SAGE ) stock isn't doing the best on Monday after the FDA weighed in on the biopharmaceutical company's depression drug zuranolone. According to Sage Therapeutics, it's unhappy with the Complete Response Letter received from the FDA concerning this drug.

Why Is Sage Therapeutics (SAGE) Stock Down 48% Today?

Sage stock plummeted Monday after the FDA approved its drug, Zurzuvae, in postpartum depression, but not major depressive disorder.

Why Sage Lost Half Its Value After The FDA Approved Its Depression Drug

Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $2.68 per share versus the Zacks Consensus Estimate of a loss of $2.53. This compares to loss of $2.13 per share a year ago.

Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Misses Revenue Estimates

Sage Therapeutics Inc.'s stock SAGE cratered 49% in premarket trade Monday, on disappointment that the U.S. regulator approved its zuranolone treatment for postpartum depression, but not for major depressive disorder, or MDD, which is a far broader condition. The Food and Drug Administration approved the treatment which was co-developed with Biogen Inc. in an announcement late Friday, making it the first-and-only oral treatment for post-partum, which affects one in eight new mothers in the U.S., according to CDC data.

Sage Therapeutics' stock craters 49% after FDA approves zuranolone for postpartum depression, but not major depressive disorder

Sage Therapeutics says it's 'evaluating resource allocation, including pipeline prioritization and a workforce reorganization with a goal of extending our cash runway.'

Sage Stock Tumbles After FDA Decision on Depression Drug

Biogen

The U.S. drug regulator's approval of Biogen and Sage Therapeutics' first-of-its-kind postpartum depression (PPD) pill is unlikely to allay the drugmakers' growth concerns, analysts said on Monday.

News for SAGE Therapeutics Stock (SAGE)